Aloe anthraquinones / IL6 Cancer Research Results

AV, Aloe anthraquinones: Click to Expand ⟱
Features:

Aloe vera — a medicinal succulent (Aloe barbadensis Miller) used as a complex botanical mixture whose clinically used preparations typically derive from (i) the inner leaf gel (polysaccharide-rich) and/or (ii) whole-leaf extracts containing anthraquinones. It is best classified as a botanical/natural product mixture (not a single agent). Common abbreviations include AV (Aloe vera). Key bioactives often discussed in oncology-adjacent literature include polysaccharides such as acemannan (immunomodulatory/wound-healing biomaterial profile) and anthraquinones such as aloe-emodin/emodin/aloin (more directly cytotoxic in vitro, but also linked to GI toxicity/carcinogenic hazard signals in certain whole-leaf preparations).

Primary mechanisms (ranked):

  1. Mitochondrial apoptosis induction in cancer models (Bax↑, Bcl-2↓, caspase activation; often attributed to anthraquinones and/or crude extracts in vitro)
  2. Inflammation and innate-immune signaling modulation (NF-κB and related cytokine axes; context-dependent, preparation-dependent)
  3. Growth/survival pathway suppression in cancer models (PI3K/AKT/mTOR and interconnected nodes; preparation-dependent)
  4. Anti-migration/anti-EMT and invasion modulation (EMT programs, MMPs; largely preclinical)
  5. Immunomodulation and tissue-repair signaling via gel polysaccharides (acemannan-driven macrophage/DC/lymphocyte activation; cytokine induction; biomaterial-like effects)
  6. Redox effects (ROS and NRF2 are preparation- and dose-dependent; antioxidant claims mainly for gel fractions, pro-oxidant/cytotoxic signaling more common with anthraquinone-rich fractions in cancer cell assays)

Bioavailability / PK relevance: Aloe preparations are heterogeneous. High–molecular-weight gel polysaccharides (e.g., acemannan) have limited systemic bioavailability and are most relevant for local mucosal/skin exposure or immune-adjacent effects; anthraquinones are more systemically absorbable but undergo metabolism and are constrained by GI tolerance and safety concerns. “Decolorized/low-anthraquinone” products differ materially from nondecolorized whole-leaf extracts.

In-vitro vs systemic exposure relevance: Many reported anticancer effects use crude extracts or isolated anthraquinones at concentrations that may exceed typical achievable systemic levels from oral supplements; supportive-care benefits (skin/mucosa) are more plausibly local exposure–driven.

Clinical evidence status: Predominantly preclinical for direct anticancer activity. Human evidence is mainly supportive-care (e.g., radiation dermatitis and oral mucositis), with mixed RCT outcomes and heterogeneous formulations; there is no high-quality evidence establishing Aloe vera as a primary anticancer therapy.

Aloe vera Therapeutic properties include: anti-microbial, anti-viral, anti-cancer, anti-oxidant, anti-inflammatory, skin protection, wound healing, and regulation of blood glucose and cholesterol.
active constituents, such as aloe-emodin and acemannan.

• Aloe vera extracts harbor antioxidant compounds that can scavenge free radicals, protecting cells from oxidative damage—a factor in aging and cancer development.

Aloe vera’s blend of bioactive compounds offers a range of biological activities—including anti-inflammatory, antioxidant, immunomodulatory, and wound-healing effects—that have attracted interest for complementary roles in health maintenance and cancer supportive care. While it is not a primary anticancer agent, its potential to mitigate treatment side effects, enhance immune responses, and possibly contribute to chemoprevention makes it a subject of ongoing research.

Aloe vera — mechanistic axes relevant to cancer and supportive care

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Mitochondrial apoptosis program Bax↑; Bcl-2↓; caspases↑ (model-dependent) ↔ / protective (context-dependent) R/G Pro-apoptotic shift Bax↑ and Bcl-2↓ in MCF-7 with AV extract; many “direct anticancer” claims are extract- or anthraquinone-driven and preclinical.
2 PI3K/AKT/mTOR survival signaling ↓ (model-dependent) ↔ R/G Reduced growth/survival signaling Frequently reported for anthraquinones (aloe-emodin/emodin/aloin) and some crude extracts; formulation is a major confounder.
3 NF-κB inflammatory signaling ↓ (often) (context-dependent) ↓ (context-dependent) P/R Anti-inflammatory signaling shift Most relevant to supportive-care phenotypes (dermatitis/mucositis) and immune microenvironment modulation rather than direct tumor cytotoxicity.
4 Immune activation by gel polysaccharides Indirect effects via immune context Macrophage/DC activation↑; cytokines↑ R/G Immunomodulation and tissue repair support Acemannan is the best-characterized polysaccharide; systemic anticancer translation remains uncertain, but local mucosal/skin benefit is plausible.
5 ROS modulation ↑ (high concentration only) or ↓ (antioxidant fractions) ↓ (antioxidant fractions) or ↔ P/R Redox stress or scavenging Direction depends strongly on preparation: gel fractions are commonly framed as antioxidant; anthraquinone-rich fractions often act pro-oxidatively in cancer assays.
6 NRF2 antioxidant-response axis ↔ / ↑ (context-dependent) ↑ (context-dependent) G Adaptive antioxidant signaling Not consistently “primary” for AV in oncology; include as secondary because redox-adaptation can modulate therapy response and inflammation.
7 EMT, migration, invasion ↓ (model-dependent) ↔ G Reduced metastatic phenotypes Mostly preclinical; often co-reported with NF-κB/PI3K-AKT changes and MMP/EMT markers.
8 Radiosensitization or Chemosensitization ↔ (insufficient clinical proof) Radioprotection reported (context-dependent) R/G Supportive-care modulation vs sensitization Human studies more often evaluate symptom mitigation (dermatitis/mucositis) than tumor response; do not infer sensitization without direct tumor-outcome trials.
9 Clinical Translation Constraint Preparation heterogeneity; polysaccharide PK limitations; anthraquinone-driven GI effects; safety signals for nondecolorized whole-leaf extracts; evidence base mostly supportive-care — Whole-leaf (nondecolorized) extracts are classified as possibly carcinogenic to humans (IARC 2B) and produced large-intestine tumors in rodent studies; “gel-only” and decolorized/low-anthraquinone products are not equivalent.


IL6, Interleukin-6: Click to Expand ⟱
Source: HalifaxProj(inhibit)
Type:
Interleukin-6 (IL-6) is a cytokine that plays a significant role in inflammation and the immune response. It is produced by various cell types, including T cells, B cells, macrophages, and fibroblasts.
IL-6 can promote tumor cell proliferation and survival. Many cancer cells produce IL-6, which can create an autocrine loop that supports their growth.
IL-6 is a high-value inflammatory biomarker in cancer, reporting cytokine burden, catabolic stress, and STAT3-linked survival signaling. While not tumor-specific, elevated and rising IL-6 strongly predicts poor prognosis and limited treatment tolerance, making it an important system-state indicator alongside CRP and ferritin.


Scientific Papers found: Click to Expand⟱
5365- AV,    Aloe Vera Polysaccharides as Therapeutic Agents: Benefits Versus Side Effects in Biomedical Applications
- Review, Nor, NA - Review, IBD, NA - Review, Diabetic, NA
*Wound Healing↑, *Imm↑, *antiOx↑, *AntiDiabetic↑, *AntiCan↑, *Inflam↓, *NF-kB↓, *COX2↓, *5LO↓, *IL1β↓, *IL6↓, *TNF-α↓, *IL10↑, *other↓, *ROS↓, *SOD↑, *Catalase↑, *GPx↑, *lipid-P↓, *DNAdam↓, *GutMicro↑, *ZO-1↑, AntiTum↑, Casp3↑, Casp9↑, angioG↓, MMPs↓, VEGF↓, NK cell↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Cell Death ⓘ

Casp3↑, 1,   Casp9↑, 1,  

Migration ⓘ

MMPs↓, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 1,   VEGF↓, 1,  

Immune & Inflammatory Signaling ⓘ

NK cell↑, 1,  

Functional Outcomes ⓘ

AntiTum↑, 1,  
Total Targets: 7

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 1,   Catalase↑, 1,   GPx↑, 1,   lipid-P↓, 1,   ROS↓, 1,   SOD↑, 1,  

Transcription & Epigenetics ⓘ

other↓, 1,  

DNA Damage & Repair ⓘ

DNAdam↓, 1,  

Migration ⓘ

5LO↓, 1,   ZO-1↑, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 1,   IL10↑, 1,   IL1β↓, 1,   IL6↓, 1,   Imm↑, 1,   Inflam↓, 1,   NF-kB↓, 1,   TNF-α↓, 1,  

Clinical Biomarkers ⓘ

GutMicro↑, 1,   IL6↓, 1,  

Functional Outcomes ⓘ

AntiCan↑, 1,   AntiDiabetic↑, 1,   Wound Healing↑, 1,  
Total Targets: 23

Scientific Paper Hit Count for: IL6, Interleukin-6
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:28  Target#:158  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page